India defers trade talks on EU drug ban; Hedge funder pushes Baxter for board seats, new CEO;

@FiercePharma: ICYMI yesterday: FDA updates label for Novartis' MS pill Gilenya after reports of brain infection. Article | Follow @FiercePharma

@EricPFierce: Aprecia is building $25M plant where it will do 3D printing of drugs. FiercePharmaManufacturing article | Follow @EricPFierce

@CarlyHFierce: Perrigo CEO: Think Mylan's buyout will come easily? Think again. More | Follow @CarlyHFierce

> India has put off free trade talks with Europe after the European Union refused to lift a ban on the sale of about 700 drugs. Report

> Billionaire hedge funder Daniel Loeb asked for two seats on the board of Baxter International ($BAX), saying he could help find a new CEO for the company. Report

> The rate of cancer survival is improving in England, but still lags other countries with similar healthcare systems. Report

> England's cost-effectiveness watchdog said it might consider making AstraZeneca's ($AZN) new drug Lynparza available to ovarian cancer patients who have already undergone three rounds of chemo. Report

Medical Device News

@FierceMedDev: DNAnexus teams up with FDA for Precision Medicine cloud-based genomics platform. More from FierceDiagnostics | Follow @FierceMedDev

@VarunSaxena2: ICYMI: Intuitive awards grants to support training of its da Vinci robot using virtual reality. Article | Follow @VarunSaxena2

@EmilyWFierce: A little news on CEO compensation. More from the WSJ | Follow @EmilyWFierce

> Global tech organization reveals new system for blood glucose monitoring devices. Story

> Medtronic recalls CoreValve TAVR component due to presence of particulate matter. News

> Miniature surgical robot startup gets $11M to assess feasibility in colon resection. Article

Biotech News

@FierceBiotech: Scripps team finds a drug that fights addiction by eliminating memories. FierceBiotechResearch story | Follow @FierceBiotech

@JohnCFierce: What's + PhII data from a small allergy study worth? Aimmune bags $160M IPO as the market continues to embrace bio. Article | Follow @JohnCFierce

@DamianFierce: "IPO (n.): An acronym for 'initial public offering' that neglects to mention the taking." More | Follow @DamianFierce

> Epizyme parts ways with its CEO ahead of big Phase II cancer bet. Item

> Eyeing first profits, Tillman Gerngross's Avitide nabs one last VC round. Report

> AstraZeneca buys a new immuno-oncology weapon in $510M Heptares deal. Article

Vaccines News

> U.K's Prokarium scores $585,000 for oral chlamydia vaccine. Report

> State vaccination laws impact outbreak rates, study finds. Item

> Merck Ebola vaccine posts 100% efficacy in PhIII. More

> Novavax reports PhII success for quadrivalent seasonal flu vax. Story

> CSL completes purchase of Novartis' flu vaccine business. Article

CRO News

> Quintiles' $950M IPO keeps on giving for PE backers. Report

> Icon gets in on the ground floor with a Novartis-backed biotech upstart. More

> Patheon signs up to manufacture Flexion's lead drug. Item

> Parexel returns to growth after a shaky quarter. Story

> INC raises its 2015 expectations after another strong quarter. Article

Pharma Manufacturing News

> India, mad over EU ban on drugs, postpones trade talks. Item

> AMRI's expansion binge pays off for CMO. Story

> FDA warning letter smacks Indian lab for repeated shortcomings. More

> French regulator found 30 cases of mold contamination in biotech plant. Report

> GSK moves foward in Bangalore with new Indian plant. Article

Pharma Asia News

> India defers EU trade talks as ban on GVK-tested drugs rankles. Item

> China-focused Mabtech licenses four mAB candidates to Sorrento. More

> BeiGene receives first China trial approval nod for BGB-283. Story

> GSK rehires former China government affairs director Shi. Report

> AstraZeneca stands out again in China, hails AZD9291 in Japan. Article

And Finally... In offering Actavis financing for its purchase of Allergan ($AGN) last year, Japan's Mizhuo Financial Group illustrated its Wall Street ambitions. Report

Suggested Articles

AbbVie has seen blossoming market share for immunology launches Rinvoq and Skyrizi—and it's eyeing Allergan's neurology biz for a boost, too.

While Novo's Rybelsus launch has slowed due to the pandemic, another version of the med, Ozempic posted strong sales.

AZ sold Atacand and Atacand Plus rights in about 70 countries to Cheplapharm.